- Incurix and AIGEN to co-develop transcription factor inhibitor based new anti-cancer drug using transcriptome-based AI platform 

Incurix made an agreement with AI-based new drug discovery biotech AIGEN Sciences for joint research on AI-based development of a new anti-cancer drug on Feb 21. Through this partnership, the two companies aim to cooperate in developing a new anti-cancer drug targeting the transcription factor inhibitor Incurix is developing, which is reportedly difficult to develop while recognized as one of the main anti-cancer targets, by applying the transcriptome profiles- based AI technology centering on AIGEN Science’s protein structure.

Under the agreement, AIGEN Sciences will discover new substances that can control transcription factors using the company’s AI platform. Incurix will further verify the effective substances and leading substances, and develop the final lead molecules, using its core technology to identify the direct inhibitor for the transcription factor. The profit secured through commercialization such as third-party licensing will be shared at a certain rate according to the development stage of the candidate drug, at the period of profit generation.  

http://www.biospectator.com/view/news_view.php?varAtcId=15584